1. Home
  2. CYTH vs OXBR Comparison

CYTH vs OXBR Comparison

Compare CYTH & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • OXBR
  • Stock Information
  • Founded
  • CYTH 1990
  • OXBR 2013
  • Country
  • CYTH United States
  • OXBR Cayman Islands
  • Employees
  • CYTH N/A
  • OXBR N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • OXBR Property-Casualty Insurers
  • Sector
  • CYTH Health Care
  • OXBR Finance
  • Exchange
  • CYTH Nasdaq
  • OXBR Nasdaq
  • Market Cap
  • CYTH 20.4M
  • OXBR 18.6M
  • IPO Year
  • CYTH N/A
  • OXBR 2014
  • Fundamental
  • Price
  • CYTH $0.63
  • OXBR $3.90
  • Analyst Decision
  • CYTH Buy
  • OXBR
  • Analyst Count
  • CYTH 3
  • OXBR 0
  • Target Price
  • CYTH $0.95
  • OXBR N/A
  • AVG Volume (30 Days)
  • CYTH 43.6K
  • OXBR 35.9K
  • Earning Date
  • CYTH 11-14-2024
  • OXBR 11-13-2024
  • Dividend Yield
  • CYTH N/A
  • OXBR N/A
  • EPS Growth
  • CYTH N/A
  • OXBR N/A
  • EPS
  • CYTH N/A
  • OXBR N/A
  • Revenue
  • CYTH $870,725.00
  • OXBR N/A
  • Revenue This Year
  • CYTH N/A
  • OXBR N/A
  • Revenue Next Year
  • CYTH $24.49
  • OXBR N/A
  • P/E Ratio
  • CYTH N/A
  • OXBR N/A
  • Revenue Growth
  • CYTH N/A
  • OXBR N/A
  • 52 Week Low
  • CYTH $0.57
  • OXBR $0.87
  • 52 Week High
  • CYTH $2.12
  • OXBR $4.19
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 46.82
  • OXBR 66.05
  • Support Level
  • CYTH $0.60
  • OXBR $3.62
  • Resistance Level
  • CYTH $0.69
  • OXBR $4.04
  • Average True Range (ATR)
  • CYTH 0.04
  • OXBR 0.26
  • MACD
  • CYTH 0.00
  • OXBR -0.01
  • Stochastic Oscillator
  • CYTH 50.00
  • OXBR 69.23

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The Company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: